Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 38 Mendeley

Summary Policy documents Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies

Article in Diabetes Therapy (February 2021)

Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature

Article in Endocrine Metabolic & Immune Disorders - Drug Targets (January 2021)

Association of glycosylated hemoglobin and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Article in Medicine (November 2020)